Mureidomycin A, a new inhibitor of bacterial peptidoglycan synthesis.

AUTOR(ES)

Isono, F

RESUMO

Mureidomycin A (MRD), a novel peptidylnucleoside antibiotic with antipseudomonal activity, inhibited not only peptidoglycan synthesis but also lipid-intermediate formation from UDP-N-acetylmuramyl (MurNAc)-pentapeptide and UDP-N-acetylglucosamine in an in vitro peptidoglycan-synthesizing system, using ether-treated cells of Pseudomonas aeruginosa. Both types of inhibition by MRD disappeared when UDP-MurNAc-pentapeptide was preincubated with ether-treated cells. Moreover, MRD completely inhibited lipid-intermediate I (undecaprenyl-p-p-MurNAc-pentapeptide) formation at a concentration below the MIC. From these results, it was concluded that the real target of MRD's action was translocase, which catalyzes lipid-intermediate I formation from UDP-MurNAc-pentapeptide and a lipid carrier.

Documentos Relacionados

• Kinetics of initiation of bacterial protein synthesis.
• Gardimycin, a New Antibiotic Inhibiting Peptidoglycan Synthesis
• Characterization of Terfestatin A, a New Specific Inhibitor for Auxin Signaling1[w]
• Mode of action of the hemin-controlled inhibitor of protein synthesis.
• A new universal linker for solid phase DNA synthesis.